Lichen myxedematosus: a case series focusing on clinical features, disease associations, and management

Atcı, Tuğba; Yazganoğlu, Kurtuluş Didem; Yonal, Ipek; Ekinci, Algün Polat; Kaplan, S; Babuna, Goncagül; Beşışık, Sevgi Kalayoğlu; Baykal, Can

doi:10.1111/ddg.12970

Cited by 8 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It may include melphalan, corticosteroids, plasmapheresis, acitretin, intravenous immunoglobulins, thalidomide, methotrexate, cyclophosphamide, cyclosporine, phototherapy and laser therapy. Topical tacrolimus ointment and topical corticosteroids have also been used successfully as a treatment option [9][10][11][12][13][14][15]. Systemic therapy with neotigason was discussed with our patient, but she decided against it and the proposed follow-up.…”

Section: Discussionmentioning

confidence: 96%

Multiple skin‐colored papules on the face and upper extremities

Kulberg

Tronnier

2019

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 96%

Multiple skin‐colored papules on the face and upper extremities

Kulberg

Tronnier

2019

J Deutsche Derma Gesell

View full text Add to dashboard Cite

“…Case reports have documented clinical improvement in patients treated with topical betamethasone and topical dimethyl sulfoxide, 74 topical and intralesional corticosteroid therapy, topical tacrolimus, 75,76 cyclosporine, 77,78 HCQ, 79 and chemotherapeutic agents including cyclophosphamide, 80‐83 MTX, 84 and 2‐chlorodeoxyadenosine 85 . Retinoids (oral isotretinoin and acitretin) 86,87 have been shown to modulate the glycosaminoglycan synthesis and reduce the mucin production by fibroblasts in SMX, leading to clinical improvement. IFN has immunomodulatory and antiproliferative effects and may play a role in the treatment of SMX 88‐90 .…”

Section: Discussionmentioning

confidence: 99%

Scleromyxedema treatment: a systematic review and update

2020

View full text Add to dashboard Cite

Importance Scleromyxedema is a chronic disease with high morbidity and mortality and no definitive therapeutic guidelines. Objective To review all available data on the efficacy and the safety of the available treatments of scleromyxedema and suggest a possible therapeutic approach. Evidence Review We performed a systematic literature review in Pubmed/Medline, Embase, and Cochrane collaboration databases, searching for all articles since 1990 on the treatments of scleromyxedema, with no limits on participant age, gender, or nationality. Findings Ninety-seven studies were included in this systematic review, of which one prospective, two retrospective, 70 case reports/case series, and 24 letters/correspondence/ clinical image. Intravenous immunoglobulin (IVIG) was the most used first-line therapy based on its efficacy and its generally well-tolerated nature; most patients require continued treatment to remain in remission. Thalidomide and systemic glucocorticoids were mostly considered as second-line therapies and were given alone or in association with IVIG. Patients with severe or refractory disease were treated with autologous bone marrow transplantation, melphalan, or bortezomib with dexamethasone. Conclusions and Relevance Consideration of patient comorbidities, disease distribution, clinician experience, and treatment accessibility is mandatory in every therapeutic approach of scleromyxedema.

show abstract

“…We retrospectively evaluated midfacial cutaneous involvement in seven LM patients who were seen in a 25 year-period in our clinic, five of whom were reported formerly. 5 The medical records including the clinical pictures of the patients were analysed in detail. The diagnosis was histopathologically confirmed from the biopsies of typical LM lesions on other body sites rather than midfacial lesions.…”

Section: Midfacial Involvement In Lichen Myxedematosus: a Clinical Pementioning

confidence: 99%